[A new method of administration of budesonide powder for the treatment of allergic rhinitis].
The efficacy and safety of a new device for administering powdered budesonide in allergic rhinitis was evaluated. This method eliminates the disadvantages of traditional preparations and improves dosing and administration, even at low nasal flow rates. A randomized, controlled, single-blind study was made in 66 patients with allergic rhinitis, half of whom were assigned to the experimental treatment (powdered budesonide) and half to a standard aerosol. Results showed that both preparations were very effective (p < 0.01) in controlling rhinitis symptoms and not significantly different. However, the overall patient evaluation was significantly better (p < 0.01) in the group treated with powdered budesonide. Both treatments elicited a similar tolerance, although tolerance of powdered budesonide was slightly better. To conclude, treatment with the new powdered budesonide dispenser was as effective and well-tolerated as standard treatment, and better accepted by patients.
Soler
R
R
Servicio de ORL, Hospital Son Dureta, Palma de Mallorca.
Mas
S
S
Pineda
J
J
Ruiz-Bravo
C
C
Palacios
R
R
Bernal
M
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D011208:Powders; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D011208:Powders; D019819:Budesonide